U.S. market Closed. Opens in 1 hour 15 minutes

BNTX | BioNTech SE Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 101.02 - 105.82
52 Week Range 76.53 - 131.49
Beta 1.15
Implied Volatility 47.46%
IV Rank 59.16%
Day's Volume 1,121,013
Average Volume 1,064,826
Shares Outstanding 239,739,752
Market Cap 24,487,018,269
Sector Healthcare
Industry Biotechnology
IPO Date 2019-10-10
Valuation
Profitability
Growth
Health
P/E Ratio -49.82
Forward P/E Ratio 4.60
EPS -2.05
1YR Price Target 208.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 6,133
Country Germany
Website BNTX
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
BNTX's peers: NVAX, CWBR, DNA, CRSP, OCEA, ENVB, HEPA, ELEV, AVRO, PTCT, KRYS, SRPT, IOVA, MDGL, NVO, VRTX
*Chart delayed
Analyzing fundamentals for BNTX we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is confidently strong. For more detailed analysis please see BNTX Fundamentals page.

Watching at BNTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on BNTX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙